Nathan Connell: New Research on Heavy Menstrual Bleeding in Women With von Willebrand Disease
Nathan Connell, Clinical Chief of Hematology at Brigham and Women’s Faulkner Hospital, shared on LinkedIn:
“New research on heavy menstrual bleeding in women with von Willebrand disease
This open-access article in Haemophilia Journal focuses on heavy menstrual bleeding (HMB) in women with von Willebrand disease.
While VWD is the most common inherited bleeding disorder, its impact on women’s health, particularly HMB, is often underdiagnosed. This research is a crucial reminder of the importance of considering underlying bleeding disorders in women presenting with HMB.
Key takeaways from the article and related research:
- HMB is a highly prevalent symptom in women with VWD, affecting a significant majority of patients.
- The article reinforces that HMB in women with VWD can lead to complications such as iron deficiency anemia, which severely impacts a person’s quality of life.
- Diagnosis can be challenging as VWF levels can fluctuate. The article stresses the importance of proper hemostatic testing and a detailed patient history to avoid misdiagnosis.
- Effective management strategies for HMB in women with VWD are discussed, including hormonal therapies, antifibrinolytic drugs, and in some cases, VWF/FVIII concentrate.
This is a vital topic for hematologists, gynecologists, and primary care physicians to collaborate on, ensuring women receive the correct diagnosis and treatment.”
Title: Prevalence and Impact of Heavy Menstrual Bleeding in Women With von Willebrand Disease Across Age Groups: A Retrospective Study
Authors: Anna Olsson, Petra Elfvinge, Eva Zetterberg, Linda Myrin-Westesson
Read the full paper here.
Stay informed with Hemostasis Today.
-
Sep 29, 2025, 12:54Microfluidic Technology Uncovers Ongoing TTP Disease Activity
-
Sep 29, 2025, 12:43Advancing Thrombosis Research: MRI-Based Methodology for Studying Thrombus Resolution
-
Sep 29, 2025, 05:58Samwel Mikaye on Understanding, Diagnosing, and Managing Deep Venous Thrombosis (DVT)
-
Sep 28, 2025, 14:08Mary Cushman: Dr Warkentin Is a Giant in Hematology
-
Sep 28, 2025, 13:31Michael Makris Highlights Vaccine Misinformation and Its Risks
-
Sep 29, 2025, 12:33Allison Wheeler: Some Days I Love Science a Little Bit More
-
Sep 29, 2025, 06:23Yudi Hardianto and Colleagues Give a Review on Stroke Rehabilitation in LMICs
-
Sep 29, 2025, 04:42Wolfgang Miesbach on the Bi8 Study: A Novel FVIII-Mimetic Antibody Gene Therapy for Haemophilia A
-
Sep 29, 2025, 04:16Salvador Payán Pernía on Equity Challenges in Access to Gene Therapy for Hemoglobinopathies
-
Sep 29, 2025, 04:02Nicolas Gendron: A Very Nice Demonstration by The Authors - Coffee is Associated with Reduced Risk of VTE
-
Sep 29, 2025, 05:06Sue Bacon on the Importance of Addressing Hospital-Acquired DVT and PE
-
Sep 24, 2025, 11:06Wolfgang Miesbach Reports Promising Results for New Subcutaneous von Willebrand Disease Therapy VGA039
-
Sep 23, 2025, 06:40Richard Buka: CSL Behring Have Announced a Collaboration with Dutch Biotech, VarmX
-
Sep 22, 2025, 07:10Aspirin Beyond the Heart․ Targeting PI3K-Altered Colorectal Cancer
-
Sep 22, 2025, 06:04ClearPlasma: A New Filter Technology to Enhance Clot Stability in Donated Plasma
-
Sep 29, 2025, 07:02Kambua Manundu: We Walked to Protest the Countless Lives of Women We Have Lost to Post Partum Hemorrhage
-
Sep 29, 2025, 06:41Ouma Oluga Unveiled Plans to Make Sickle Cell Screening Mandatory in Kenya at 80th UN General Assembly
-
Sep 29, 2025, 04:51Nathan Connell on Breakthrough Gene Therapy Advancing Care for People with Hemophilia
-
Sep 29, 2025, 04:28Emmeran Hauser: Fantastic to See First Results of Our Work in Europe
-
Sep 28, 2025, 10:33Côme Bommier: Burnout Is Common Among Hematology Professionals